Atlas Trials

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Clinical trial NCT07283679 · RECRUITING

Trial details

NCT number
NCT07283679
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-cell Non-Hodgkin Lymphoma
Start date
2026-02-24
Primary completion
2031-09-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.